Monica M Vasquez1, Leslie A McClure2, Duane L Sherrill1, Sanjay R Patel3, Jerry Krishnan4, Stefano Guerra5, Sairam Parthasarathy6. 1. Arizona Respiratory Center, University of Arizona, Tucson. 2. Dornsife School of Public Health, Drexel University, Philadelphia, Pa. 3. Department of Medicine, University of Pittsburgh, Pa. 4. Office of Health Affairs at the University of Illinois Hospital & Health Sciences System, Chicago. 5. Arizona Respiratory Center, University of Arizona, Tucson; Department of Medicine, University of Arizona, Tucson; CREAL Centre and Universitat Pompeu Fabra, Barcelona, Spain. 6. Department of Medicine, University of Arizona, Tucson; UAHS Center for Sleep & Circadian Sciences, University of Arizona, Tucson. Electronic address: Spartha1@email.arizona.edu.
Abstract
BACKGROUND: Hospitalization of patients with chronic obstructive pulmonary disease creates a huge healthcare burden. Positive airway pressure therapy is sometimes used in patients with chronic obstructive pulmonary disease, but the possible impact on hospitalization risk remains controversial. We studied the hospitalization risk of patients with chronic obstructive pulmonary disease before and after initiation of various positive airway pressure therapies in a "real-world" bioinformatics study. METHODS: We performed a retrospective analysis of administrative claims data of hospitalizations in patients with chronic obstructive pulmonary disease who received or did not receive positive airway pressure therapy: continuous positive airway pressure, bilevel positive airway pressure, and noninvasive positive pressure ventilation using a home ventilator. RESULTS: The majority of 1,881,652 patients with chronic obstructive pulmonary disease (92.5%) were not receiving any form of positive airway pressure therapy. Prescription of bilevel positive airway pressure (1.5%), continuous positive airway pressure (5.6%), and noninvasive positive pressure ventilation (<1%) in patients with chronic obstructive pulmonary disease demonstrated geographic-, sex-, and age-related variability. After adjusting for confounders and propensity score, noninvasive positive pressure ventilation (odds ratio [OR], 0.19; 95% confidence interval [CI], 0.13-0.27), bilevel positive airway pressure (OR, 0.42; 95% CI, 0.39-0.45), and continuous positive airway pressure (OR, 0.70; 95% CI, 0.67-0.72) were individually associated with lower hospitalization risk in the 6 months post-treatment when compared with the 6 months pretreatment but not when compared with the baseline period between 12 and 6 months before treatment initiation. Stratified analysis suggests that comorbid sleep-disordered breathing, chronic respiratory failure, heart failure, and age less than 65 years were associated with greater benefits from positive airway pressure therapy. CONCLUSION: Initiation of positive airway pressure therapy was associated with reduction in hospitalization among patients with chronic obstructive pulmonary disease, but the causality needs to be determined by randomized controlled trials.
BACKGROUND: Hospitalization of patients with chronic obstructive pulmonary disease creates a huge healthcare burden. Positive airway pressure therapy is sometimes used in patients with chronic obstructive pulmonary disease, but the possible impact on hospitalization risk remains controversial. We studied the hospitalization risk of patients with chronic obstructive pulmonary disease before and after initiation of various positive airway pressure therapies in a "real-world" bioinformatics study. METHODS: We performed a retrospective analysis of administrative claims data of hospitalizations in patients with chronic obstructive pulmonary disease who received or did not receive positive airway pressure therapy: continuous positive airway pressure, bilevel positive airway pressure, and noninvasive positive pressure ventilation using a home ventilator. RESULTS: The majority of 1,881,652 patients with chronic obstructive pulmonary disease (92.5%) were not receiving any form of positive airway pressure therapy. Prescription of bilevel positive airway pressure (1.5%), continuous positive airway pressure (5.6%), and noninvasive positive pressure ventilation (<1%) in patients with chronic obstructive pulmonary disease demonstrated geographic-, sex-, and age-related variability. After adjusting for confounders and propensity score, noninvasive positive pressure ventilation (odds ratio [OR], 0.19; 95% confidence interval [CI], 0.13-0.27), bilevel positive airway pressure (OR, 0.42; 95% CI, 0.39-0.45), and continuous positive airway pressure (OR, 0.70; 95% CI, 0.67-0.72) were individually associated with lower hospitalization risk in the 6 months post-treatment when compared with the 6 months pretreatment but not when compared with the baseline period between 12 and 6 months before treatment initiation. Stratified analysis suggests that comorbid sleep-disordered breathing, chronic respiratory failure, heart failure, and age less than 65 years were associated with greater benefits from positive airway pressure therapy. CONCLUSION: Initiation of positive airway pressure therapy was associated with reduction in hospitalization among patients with chronic obstructive pulmonary disease, but the causality needs to be determined by randomized controlled trials.
Authors: Bartolome R Celli; Marc Decramer; Jadwiga A Wedzicha; Kevin C Wilson; Alvar Agustí; Gerard J Criner; William MacNee; Barry J Make; Stephen I Rennard; Robert A Stockley; Claus Vogelmeier; Antonio Anzueto; David H Au; Peter J Barnes; Pierre-Regis Burgel; Peter M Calverley; Ciro Casanova; Enrico M Clini; Christopher B Cooper; Harvey O Coxson; Daniel J Dusser; Leonardo M Fabbri; Bonnie Fahy; Gary T Ferguson; Andrew Fisher; Monica J Fletcher; Maurice Hayot; John R Hurst; Paul W Jones; Donald A Mahler; François Maltais; David M Mannino; Fernando J Martinez; Marc Miravitlles; Paula M Meek; Alberto Papi; Klaus F Rabe; Nicolas Roche; Frank C Sciurba; Sanjay Sethi; Nikos Siafakas; Don D Sin; Joan B Soriano; James K Stoller; Donald P Tashkin; Thierry Troosters; Geert M Verleden; Johny Verschakelen; Jorgen Vestbo; John W Walsh; George R Washko; Robert A Wise; Emiel F M Wouters; Richard L ZuWallack Journal: Am J Respir Crit Care Med Date: 2015-04-01 Impact factor: 21.405
Authors: R D McEvoy; R J Pierce; D Hillman; A Esterman; E E Ellis; P G Catcheside; F J O'Donoghue; D J Barnes; R R Grunstein Journal: Thorax Date: 2009-02-12 Impact factor: 9.139
Authors: Claudia Crimi; Alberto Noto; Pietro Princi; Antoine Cuvelier; Juan F Masa; Anita Simonds; Mark W Elliott; Peter Wijkstra; Wolfram Windisch; Stefano Nava Journal: COPD Date: 2016-01-08 Impact factor: 2.409
Authors: David Gordon; Wendy Taddei-Peters; Alice Mascette; Melissa Antman; Peter G Kaufmann; Michael S Lauer Journal: N Engl J Med Date: 2013-11-14 Impact factor: 91.245
Authors: Pilar Carrasco Garrido; Javier de Miguel Díez; Javier Rejas Gutiérrez; Antonio Martín Centeno; Elena Gobartt Vázquez; Angel Gil de Miguel; Marta García Carballo; Rodrigo Jiménez García Journal: Health Qual Life Outcomes Date: 2006-05-23 Impact factor: 3.186
Authors: Lucas M Donovan; Laura C Feemster; Edmunds M Udris; Matthew F Griffith; Laura J Spece; Brian N Palen; Ken He; Sairam Parthasarathy; Kingman P Strohl; Vishesh K Kapur; David H Au Journal: J Clin Sleep Med Date: 2019-01-15 Impact factor: 4.062